Evidence map›Paper›PMID 33977921›Full record

ArticleChemical communications (Cambridge, England)2021

Axel Steinbrueck, Adam C Sedgwick, Hai-Hao Han, Michael Y Zhao, Sajal Sen, Dan-Ying Huang, Yi Zang, Jia Li, Xiao-Peng He, Jonathan L Sessler

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemical communications (Cambridge, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Targeting iron to contrast cancer progression.Current opinion in chemical biology · 2023
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Axel SteinbrueckDepartment of Chemistry, University of Texas at Austin, 105 E 24th street A5300, Austin, TX 78712-1224, USA. sessler@cm.utexas.edu.ORCID http://orcid.org/0000-0001-6014-3204
Adam C SedgwickDepartment of Chemistry, University of Texas at Austin, 105 E 24th street A5300, Austin, TX 78712-1224, USA. sessler@cm.utexas.edu.
Hai-Hao HanKey Laboratory for Advanced Materials and Joint International Research Laboratory of Precision Chemistry and Molecular Engineering, Feringa Nobel Prize Scientist Joint Research Center, Frontiers Center for Materiobiology and Dynamic Chemistry, School of Chemistry and Molecular Engineering, East China University of Science and Technology, 130 Meilong Rd., Shanghai 200237, China. xphe@ecust.edu.cn.
Michael Y ZhaoDepartment of Chemistry, University of Texas at Austin, 105 E 24th street A5300, Austin, TX 78712-1224, USA. sessler@cm.utexas.edu.
Sajal SenDepartment of Chemistry, University of Texas at Austin, 105 E 24th street A5300, Austin, TX 78712-1224, USA. sessler@cm.utexas.edu.ORCID http://orcid.org/0000-0002-1189-4156
Dan-Ying HuangDepartment of Chemistry, University of Texas at Austin, 105 E 24th street A5300, Austin, TX 78712-1224, USA. sessler@cm.utexas.edu.
Yi ZangNational Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, P. R. China. jli@simm.ac.cn.
Jia LiNational Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, P. R. China. jli@simm.ac.cn.
Xiao-Peng HeKey Laboratory for Advanced Materials and Joint International Research Laboratory of Precision Chemistry and Molecular Engineering, Feringa Nobel Prize Scientist Joint Research Center, Frontiers Center for Materiobiology and Dynamic Chemistry, School of Chemistry and Molecular Engineering, East China University of Science and Technology, 130 Meilong Rd., Shanghai 200237, China. xphe@ecust.edu.cn.
Jonathan L SesslerDepartment of Chemistry, University of Texas at Austin, 105 E 24th street A5300, Austin, TX 78712-1224, USA. sessler@cm.utexas.edu.ORCID http://orcid.org/0000-0002-9576-1325
The University of Texas at Austin · USChinese Academy of Sciences · CNEast China University of Science and Technology · CN

Funding

Biomedical Applications of Expanded Porphyrins: Development of Gold-Texaphyrin ConjugatesR01CA068682 · NCI · UNIVERSITY OF TEXAS AUSTIN · PI Esther Y. Maier, Emily L Que · 1995 to 2026
$7.4M
NCI NIH HHS R01 CA068682
6 · The paper itself

Abstract

We report here strategic functionalization of the FDA approved chelator deferasirox (1) in an effort to produce organelle-targeting iron chelators with enhanced activity against A549 lung cancer cells. Derivative 8 was found to have improved antiproliferative activity relative to 1. Fluorescent cell imaging revealed that compound 8 preferentially localises within the lysosome.

Indexed as

A549 CellsAntineoplastic AgentsCell ProliferationDeferasiroxDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansIron Chelating AgentsLung NeoplasmsLysosomesMicroscopy, ConfocalMolecular StructureOptical ImagingOrganellesAntineoplastic AgentsDeferasiroxIron Chelating Agents

Identifiers

PMID33977921
PMCPMC8456774
OpenAlexW3158485502

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.